{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:25:27Z","timestamp":1787855127726,"version":"build-2784847793"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02610-4","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T01:53:37Z","timestamp":1766714017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3285-0784","authenticated-orcid":false,"given":"Zahra","family":"Jafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1029-751X","authenticated-orcid":false,"given":"Atieh","family":"Raoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6355-6378","authenticated-orcid":false,"given":"Seyyed Shamsadin","family":"Athari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bahramkiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-5096","authenticated-orcid":false,"given":"Davood","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"10","key":"2610_CR1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1177\/0022034519864112","volume":"98","author":"BR Heath","year":"2019","unstructured":"Heath BR, Michmerhuizen NL, Donnelly CR, Sansanaphongpricha K, Sun D, Brenner JC, et al. Head and neck cancer immunotherapy beyond the checkpoint Blockade. J Dent Res. 2019;98(10):1073\u201380.","journal-title":"J Dent Res"},{"issue":"1","key":"2610_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jnci\/djad156","volume":"116","author":"J Tasoulas","year":"2024","unstructured":"Tasoulas J, Farquhar DR, Sheth S, Hackman T, Yarbrough WG, Agala CB, et al. Poor oral health influences head and neck cancer patient survival: an international head and neck cancer epidemiology consortium pooled analysis. J Natl Cancer Inst. 2024;116(1):105\u201314.","journal-title":"J Natl Cancer Inst"},{"key":"2610_CR3","doi-asserted-by":"crossref","unstructured":"Liberale C, Soloperto D, Marchioni A, Monzani D, Sacchetto L. Updates on larynx cancer: risk factors and oncogenesis. Int J Mol Sci. 2023;24(16):12913.","DOI":"10.3390\/ijms241612913"},{"issue":"1","key":"2610_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/njcp.njcp_310_18","volume":"22","author":"AF Alfouzan","year":"2019","unstructured":"Alfouzan AF. Head and neck cancer pathology: old world versus new world disease. Niger J Clin Pract. 2019;22(1):1\u20138.","journal-title":"Niger J Clin Pract"},{"issue":"23","key":"2610_CR5","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.3390\/cancers13235889","volume":"13","author":"R Julian","year":"2021","unstructured":"Julian R, Savani M, Bauman JE. Immunotherapy approaches in HPV-Associated head and neck cancer. Cancers. 2021;13(23):5889.","journal-title":"Cancers"},{"key":"2610_CR6","doi-asserted-by":"crossref","unstructured":"Von Witzleben A, Wang C, Laban S, Savelyeva N, Ottensmeier CH. HNSCC: tumour antigens and their targeting by immunotherapy. Cells. 2020;9(9):2130.","DOI":"10.3390\/cells9092103"},{"issue":"8","key":"2610_CR7","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","volume":"64","author":"Y Si","year":"2016","unstructured":"Si Y, Deng Z, Lan G, Du H, Wang Y, Si J, et al. The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: A phase I clinical trial and Two-Year Follow-Up. Chem Pharm Bull (Tokyo). 2016;64(8):1118\u201323.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"2","key":"2610_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/cco.2016.03.08","volume":"5","author":"A Jain","year":"2016","unstructured":"Jain A, Chia WK, Toh HC. Immunotherapy for nasopharyngeal cancer-a review. Chin Clin Oncol. 2016;5(2):22.","journal-title":"Chin Clin Oncol"},{"key":"2610_CR9","doi-asserted-by":"crossref","unstructured":"Wang HQ, Fu R, Man QW, Yang G, Liu B, Bu LL. Advances in CAR-T cell therapy in head and neck squamous cell carcinoma. J Clin Med. 2023;12(6):2173.","DOI":"10.3390\/jcm12062173"},{"issue":"14","key":"2610_CR10","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.7150\/ijbs.47068","volume":"16","author":"Q Xu","year":"2020","unstructured":"Xu Q, Fang M, Zhu J, Dong H, Cao J, Yan L, et al. Insights into nanomedicine for immunotherapeutics in squamous cell carcinoma of the head and neck. Int J Biol Sci. 2020;16(14):2506\u201317.","journal-title":"Int J Biol Sci"},{"key":"2610_CR11","doi-asserted-by":"publisher","first-page":"6859","DOI":"10.3390\/curroncol30070501","volume":"30","author":"M Henry","year":"2023","unstructured":"Henry M. Psychosocial oncology: optimizing outcomes through interdisciplinary care in head and neck oncology. Curr Oncol. 2023;30:6859\u201361.","journal-title":"Curr Oncol"},{"key":"2610_CR12","doi-asserted-by":"crossref","unstructured":"Farah CS, John K, Wu J, editors. Contemporary assessment and management of head and neck cancer surgical margins. 2015.","DOI":"10.5772\/60066"},{"issue":"Suppl 7","key":"2610_CR13","doi-asserted-by":"publisher","first-page":"vii195","DOI":"10.1093\/annonc\/mdn447","volume":"19","author":"J Giralt","year":"2008","unstructured":"Giralt J, Benavente S, Argu\u00eds M. Optimizing approaches to head and neck cancer: strengths and weaknesses in multidisciplinary treatments of locally advanced disease. Annals Oncology: Official J Eur Soc Med Oncol. 2008;19(Suppl 7):vii195\u20139.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"2610_CR14","doi-asserted-by":"crossref","unstructured":"Shibata H, Saito S, Uppaluri R. Immunotherapy for head and neck cancer: a paradigm shift from induction chemotherapy to neoadjuvant immunotherapy. Front Oncol. 2021;11:727433.","DOI":"10.3389\/fonc.2021.727433"},{"key":"2610_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/978-3-032-00767-4_202","volume-title":"Cancer and targeting the immune system: tumor vaccines and immunotherapy","author":"A Esmaeilzadeh","year":"2025","unstructured":"Esmaeilzadeh A, Jafari D, Ghaebi M, Elahi R, Afshari F, Karimi L. Immune gene therapy of cancer. In: Rezaei N, editor. Cancer and targeting the immune system: tumor vaccines and immunotherapy. Cham: Springer Nature Switzerland; 2025. pp. 655\u201399."},{"issue":"1","key":"2610_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","volume":"3","author":"S Senapati","year":"2018","unstructured":"Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Therapy. 2018;3(1):7.","journal-title":"Signal Transduct Target Therapy"},{"issue":"20","key":"2610_CR17","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1002\/cncr.31675","volume":"124","author":"N Osazuwa-Peters","year":"2018","unstructured":"Osazuwa-Peters N, Simpson MC, Zhao L, Boakye EA, Olomukoro SI, Deshields T, et al. Suicide risk among cancer survivors: head and neck versus other cancers. Cancer. 2018;124(20):4072\u20139.","journal-title":"Cancer"},{"key":"2610_CR18","doi-asserted-by":"crossref","unstructured":"Cremolini C, Vitale E, Rastaldo R, Giachino C. Advanced nanotechnology for enhancing immune checkpoint Blockade therapy. Nanomaterials (Basel). 2021;11(3):661.","DOI":"10.3390\/nano11030661"},{"key":"2610_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-3-030-50287-4_15","volume-title":"Cancer immunology: bench to bedside immunotherapy of cancers","author":"A-H Zarnani","year":"2021","unstructured":"Zarnani A-H, Jafari D, Bozorgmehr M, Shabani M, Barzegar-Yarmohammadi L, Ghaemimanesh F, et al. Monoclonal antibodies for cancer immunotherapy. In: Rezaei N, editor. Cancer immunology: bench to bedside immunotherapy of cancers. Cham: Springer International Publishing; 2021. pp. 273\u2013312."},{"key":"2610_CR20","doi-asserted-by":"crossref","unstructured":"Pereira D, Martins D, Mendes F. Immunotherapy in head and neck cancer When, How, and why? Biomedicines. 2022;10(9):2151.","DOI":"10.3390\/biomedicines10092151"},{"issue":"1","key":"2610_CR21","doi-asserted-by":"publisher","first-page":"2403170","DOI":"10.1080\/21645515.2024.2403170","volume":"20","author":"Q Wang","year":"2024","unstructured":"Wang Q, Pan G, Zhang Y, Ni Y, Mu Y, Luo D. Emerging insights into thyroid cancer from immunotherapy perspective: A bibliometric analysis. Hum Vaccin Immunother. 2024;20(1):2403170.","journal-title":"Hum Vaccin Immunother"},{"key":"2610_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.colsurfb.2014.12.041","volume":"126","author":"M Estanqueiro","year":"2015","unstructured":"Estanqueiro M, Amaral MH, Concei\u00e7\u00e3o J, Sousa Lobo JM. Nanotechnological carriers for cancer chemotherapy: the state of the Art. Colloids Surf B Biointerfaces. 2015;126:631\u201348.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"11","key":"2610_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","volume":"7","author":"RK Jain","year":"2010","unstructured":"Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Reviews Clin Oncol. 2010;7(11):653\u201364.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"2610_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2610_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The Blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2610_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-981-32-9717-3_8","volume":"1189","author":"T Okazaki","year":"2019","unstructured":"Okazaki T, Okazaki I-m. Stimulatory and inhibitory Co-signals in autoimmunity. Adv Exp Med Biol. 2019;1189:213\u201332.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"2610_CR27","doi-asserted-by":"publisher","first-page":"111232","DOI":"10.1016\/j.humimm.2025.111232","volume":"86","author":"M Sharafi Monfared","year":"2025","unstructured":"Sharafi Monfared M, Nazmi S, Parhizkar F, Jafari D. Soluble B7 and TNF family in colorectal cancer: serum level, prognostic and treatment value. Hum Immunol. 2025;86(2):111232.","journal-title":"Hum Immunol"},{"key":"2610_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10555-017-9694-9","volume":"36","author":"P Zolkind","year":"2017","unstructured":"Zolkind P, Uppaluri R. Checkpoint immunotherapy in head and neck cancers. Cancer Metastasis Rev. 2017;36:475\u201389.","journal-title":"Cancer Metastasis Rev"},{"key":"2610_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1615\/CritRevImmunol.v18.i5.10","volume":"18 5","author":"EA Greenfield","year":"1998","unstructured":"Greenfield EA, Nguyen K, Kuchroo VK. CD28\/B7 costimulation: a review. Crit Rev Immunol. 1998;18 5:389\u2013418.","journal-title":"Crit Rev Immunol"},{"issue":"8","key":"2610_CR30","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.4049\/jimmunol.174.8.4803","volume":"174","author":"KI Mead","year":"2005","unstructured":"Mead KI, Zheng Y, Manzotti CN, Perry LC, Liu MK, Burke F, et al. Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells. J Immunol. 2005;174(8):4803\u201311.","journal-title":"J Immunol"},{"key":"2610_CR31","doi-asserted-by":"publisher","first-page":"9429","DOI":"10.1074\/jbc.M111.304329","volume":"287","author":"OS Qureshi","year":"2012","unstructured":"Qureshi OS, Kaur S, Hou TZ, Jeffery LE, Poulter NS, Briggs Z, et al. Constitutive Clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J Biol Chem. 2012;287:9429\u201340.","journal-title":"J Biol Chem"},{"issue":"5","key":"2610_CR32","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1073\/pnas.051632398","volume":"98","author":"TJ Sullivan","year":"2001","unstructured":"Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, et al. Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated Inhibition of T cell activation. Proc Natl Acad Sci U S A. 2001;98(5):2587\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2610_CR33","doi-asserted-by":"crossref","unstructured":"Wang CW, Biswas PK, Islam A, Chen MK, Chueh PJ. The use of immune regulation in treating head and neck squamous cell carcinoma (HNSCC). Cells. 2024;13(5):413.","DOI":"10.3390\/cells13050413"},{"issue":"1","key":"2610_CR34","doi-asserted-by":"publisher","first-page":"e000391","DOI":"10.1136\/jitc-2019-000391","volume":"8","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, et al. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10\u00a0mg\/kg with 3\u00a0mg\/kg in patients with advanced melanoma. J Immunother Cancer. 2020;8(1):e000391.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"2610_CR35","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/annonc\/mdz286","volume":"30","author":"V Simmet","year":"2019","unstructured":"Simmet V, Eberst L, Marabelle A, Cassier PA. Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? Ann Oncol. 2019;30(11):1751\u20139.","journal-title":"Ann Oncol"},{"issue":"11","key":"2610_CR36","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480\u201392.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2610_CR37","doi-asserted-by":"publisher","first-page":"e70072","DOI":"10.1111\/1759-7714.70072","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Wang L, Liu Y. Current status of immune checkpoint inhibitors and treatment responsive biomarkers for Triple-Negative breast cancer. Thorac Cancer. 2025;16(9):e70072.","journal-title":"Thorac Cancer"},{"issue":"4","key":"2610_CR38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"2610_CR39","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","volume":"75","author":"Z Sun","year":"2015","unstructured":"Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, et al. IL10 and PD-1 cooperate to limit the activity of Tumor-Specific CD8\u2009+\u2009T cells. Cancer Res. 2015;75(8):1635\u201344.","journal-title":"Cancer Res"},{"issue":"3","key":"2610_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359\u201370.","journal-title":"Mol Cell"},{"issue":"8","key":"2610_CR41","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537\u201344.","journal-title":"Blood"},{"issue":"1\u20133","key":"2610_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","volume":"574","author":"KA Sheppard","year":"2004","unstructured":"Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574(1\u20133):37\u201341.","journal-title":"FEBS Lett"},{"key":"2610_CR43","doi-asserted-by":"crossref","unstructured":"Zhao Y, Liu L, Weng L. Comparisons of underlying Mechanisms, clinical efficacy and safety between Anti-PD-1 and Anti-PD-L1 immunotherapy: the state-of-the-art review and future perspectives. Front Pharmacol. 2021;12:714483.","DOI":"10.3389\/fphar.2021.714483"},{"issue":"11","key":"2610_CR44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ni.1790","volume":"10","author":"BT Fife","year":"2009","unstructured":"Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR\u2013induced stop signal. Nat Immunol. 2009;10(11):1185\u201392.","journal-title":"Nat Immunol"},{"issue":"1","key":"2610_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2610_CR46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MOO.0000000000000448","volume":"26","author":"S Alfieri","year":"2018","unstructured":"Alfieri S, Cavalieri S, Licitra L. Immunotherapy for recurrent\/metastatic head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2018;26(2):152\u20136.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"11","key":"2610_CR47","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni988","volume":"4","author":"CA Sabatos","year":"2003","unstructured":"Sabatos CA, Chakravarti S, Cha E, Schubart A, S\u00e1nchez-Fueyo A, Zheng XX, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102\u201310.","journal-title":"Nat Immunol"},{"issue":"6","key":"2610_CR48","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","volume":"10","author":"Y Lv","year":"2023","unstructured":"Lv Y, Ma X, Ma Y, Du Y, Feng J. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis. 2023;10(6):2366\u201382.","journal-title":"Genes Dis"},{"key":"2610_CR49","doi-asserted-by":"crossref","unstructured":"Shil RK, Mohammed NBB, Dimitroff CJ. Galectin-9 \u2013 ligand axis: an emerging therapeutic target for multiple myeloma. Front Immunol. 2024;15:1469794.","DOI":"10.3389\/fimmu.2024.1469794"},{"issue":"1","key":"2610_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","volume":"12","author":"Z Mei","year":"2020","unstructured":"Mei Z, Huang J, Qiao B, Lam AK-y. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020;12(1):16.","journal-title":"Int J Oral Sci"},{"issue":"5","key":"2610_CR51","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2326-6066.CIR-16-0333","volume":"5","author":"HB Jie","year":"2017","unstructured":"Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1(+) and TIM-3(+) TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. Cancer Immunol Res. 2017;5(5):408\u201316.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2610_CR52","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/jop.12883","volume":"48","author":"H Wang","year":"2019","unstructured":"Wang H, Mao L, Zhang T, Zhang L, Wu Y, Guo W, et al. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients. J Oral Pathol Med. 2019;48(8):669\u201376.","journal-title":"J Oral Pathol Med"},{"key":"2610_CR53","doi-asserted-by":"publisher","first-page":"107145","DOI":"10.1016\/j.oraloncology.2024.107145","volume":"161","author":"A-K Struckmeier","year":"2025","unstructured":"Struckmeier A-K, Gosau M, Smeets R. Immunotherapeutic strategies beyond the PD-1\/PD-L1 pathway in head and neck squamous cell carcinoma \u2013 a scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA. Oral Oncol. 2025;161:107145.","journal-title":"Oral Oncol"},{"issue":"3","key":"2610_CR54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00262-016-1799-4","volume":"65","author":"B Zhang","year":"2016","unstructured":"Zhang B, Zhao W, Li H, Chen Y, Tian H, Li L, et al. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155. Cancer Immunol Immunother. 2016;65(3):305\u201314.","journal-title":"Cancer Immunol Immunother"},{"key":"2610_CR55","doi-asserted-by":"crossref","unstructured":"Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Cesne AL. LAG-3 inhibitors: novel immune checkpoint inhibitors changing the landscape of immunotherapy. Biomedicines. 2023;11(7):1878.","DOI":"10.3390\/biomedicines11071878"},{"issue":"1","key":"2610_CR56","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"key":"2610_CR57","doi-asserted-by":"crossref","unstructured":"Liu S, Wang R, Fang J. Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma. Discover Oncol. 2024;15(1):22.","DOI":"10.1007\/s12672-024-00870-z"},{"key":"2610_CR58","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","volume":"457","author":"R Saleh","year":"2019","unstructured":"Saleh R, Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019;457:168\u201379.","journal-title":"Cancer Lett"},{"key":"2610_CR59","doi-asserted-by":"publisher","first-page":"153303382211505","DOI":"10.1177\/15330338221150559","volume":"22","author":"A Khadela","year":"2023","unstructured":"Khadela A, Shah Y, Mistry P, Bodiwala K, Cb A. Immunomodulatory therapy in head and neck squamous cell carcinoma: recent advances and clinical prospects. Technol Cancer Res Treat. 2023;22:15330338221150559.","journal-title":"Technol Cancer Res Treat"},{"issue":"7","key":"2610_CR60","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41401-020-0426-2","volume":"41","author":"H-j Yu","year":"2020","unstructured":"Yu H-j, De Geest BG. Nanomedicine and cancer immunotherapy. Acta Pharmacol Sin. 2020;41(7):879\u201380.","journal-title":"Acta Pharmacol Sin"},{"key":"2610_CR61","doi-asserted-by":"publisher","first-page":"955920","DOI":"10.3389\/fimmu.2022.955920","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Liu X, Liu X, Yu J, Bai X, Wu X, et al. Combination of phototherapy with immune checkpoint blockade: theory and practice in cancer. Front Immunol. 2022;13:955920.","journal-title":"Front Immunol"},{"issue":"5","key":"2610_CR62","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1136\/emermed-2018-208091","volume":"36","author":"O Peyrony","year":"2019","unstructured":"Peyrony O, Tieghem Y, Franchitti J, Ellouze S, Morra I, Madelaine-Chambrin I, et al. Immune checkpoint Blockade toxicity among patients with cancer presenting to the emergency department. Emerg Med J. 2019;36(5):306\u20139.","journal-title":"Emerg Med J"},{"key":"2610_CR63","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3389\/fphar.2019.01254","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang H, Mustafa A, Liu S, Liu J, Lv D, Yang H, et al. Immune checkpoint inhibitor toxicity in head and neck cancer: from identification to management. Front Pharmacol. 2019;10:1254.","journal-title":"Front Pharmacol"},{"key":"2610_CR64","doi-asserted-by":"crossref","unstructured":"Meng W, Huang L, Guo J, Xin Q, Liu J, Hu Y. Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance. Pharmaceutics. 2024;16:1549.","DOI":"10.3390\/pharmaceutics16121549"},{"issue":"1","key":"2610_CR65","doi-asserted-by":"publisher","first-page":"2426755","DOI":"10.1080\/07853890.2024.2426755","volume":"57","author":"Z Wu","year":"2025","unstructured":"Wu Z, Zhang J, Li L, Wang Z, Yang C. Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors. Ann Med. 2025;57(1):2426755.","journal-title":"Ann Med"},{"key":"2610_CR66","doi-asserted-by":"publisher","first-page":"106719","DOI":"10.1016\/j.oraloncology.2024.106719","volume":"150","author":"S Cabezas-Camarero","year":"2024","unstructured":"Cabezas-Camarero S, V\u00e1zquez Masedo G, Puebla-D\u00edaz F, Corona JA, P\u00e9rez-Segura P. Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer. Oral Oncol. 2024;150:106719.","journal-title":"Oral Oncol"},{"issue":"6","key":"2610_CR67","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2217\/imt-2020-0070","volume":"13","author":"L Tang","year":"2021","unstructured":"Tang L, Liu T, Chen J, Dang J, Li G. Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis. Immunotherapy. 2021;13(6):541\u201355.","journal-title":"Immunotherapy"},{"issue":"2","key":"2610_CR68","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/lary.30971","volume":"134","author":"Y Huang","year":"2024","unstructured":"Huang Y, Zhou H, Zhao G, Wang M, Luo J, Liu J. Immune checkpoint inhibitors serve as the First-Line treatment for advanced head and neck cancer. Laryngoscope. 2024;134(2):749\u201361.","journal-title":"Laryngoscope"},{"issue":"6","key":"2610_CR69","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/JCMA.0000000000000740","volume":"85","author":"CL Lai","year":"2022","unstructured":"Lai CL, Chen TH, Chang PM, Tai SK, Chu PY, Yang MH. Efficacy of cetuximab-containing regimens in the treatment of recurrent\/metastatic head and neck cancer after progression to immune checkpoint inhibitors. J Chin Med Assoc. 2022;85(6):687\u201392.","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"2610_CR70","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1159\/000540242","volume":"17","author":"S Koyama","year":"2024","unstructured":"Koyama S, Ehara H, Donishi R, Taira K, Fukuhara T, Fujiwara K. Therapeutic host anticancer immune response through photoimmunotherapy for head and neck cancer May overcome resistance to immune checkpoint inhibitors. Case Rep Oncol. 2024;17(1):913\u201320.","journal-title":"Case Rep Oncol"},{"issue":"2","key":"2610_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.7150\/ijms.10083","volume":"12","author":"TT Wu","year":"2015","unstructured":"Wu TT, Zhou SH. Nanoparticle-based targeted therapeutics in head-and-neck cancer. Int J Med Sci. 2015;12(2):187\u2013200.","journal-title":"Int J Med Sci"},{"issue":"n\/a","key":"2610_CR72","first-page":"2403059","volume":"n\/a","author":"P Singh","year":"2024","unstructured":"Singh P, Pandit S, Balusamy SR, Madhusudanan M, Singh H, Amsath Haseef HM, et al. Advanced nanomaterials for cancer therapy: Gold, Silver, and iron oxide nanoparticles in oncological applications. Adv Healthc Mater. 2024;n\/a(n\/a):2403059.","journal-title":"Adv Healthc Mater"},{"key":"2610_CR73","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jddst.2017.12.008","volume":"44","author":"PS Kumar","year":"2018","unstructured":"Kumar PS, Jeyalatha MV, Malathi J, Ignacimuthu S. Anticancer effects of one-pot synthesized biogenic gold nanoparticles (Mc-AuNps) against laryngeal carcinoma. J Drug Deliv Sci Technol. 2018;44:118\u201328.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2610_CR74","doi-asserted-by":"crossref","unstructured":"Li C, Fang Y, Xu S, Zhao J, Dong D, Li S. Nanomedicine in HNSCC therapy-a challenge to conventional therapy. Front Pharmacol. 2024;15:1434994.","DOI":"10.3389\/fphar.2024.1434994"},{"key":"2610_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jare.2018.06.005","volume":"15","author":"S Hossen","year":"2019","unstructured":"Hossen S, Hossain MK, Basher MK, Mia MNH, Rahman MT, Uddin MJ. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J Adv Res. 2019;15:1\u201318.","journal-title":"J Adv Res"},{"issue":"1","key":"2610_CR76","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","volume":"9","author":"B Wang","year":"2024","unstructured":"Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Therapy. 2024;9(1):200.","journal-title":"Signal Transduct Target Therapy"},{"issue":"3","key":"2610_CR77","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0168-3659(00)00367-9","volume":"70","author":"HM Redhead","year":"2001","unstructured":"Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release. 2001;70(3):353\u201363.","journal-title":"J Control Release"},{"issue":"7","key":"2610_CR78","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/jps.20094","volume":"93","author":"J Panyam","year":"2004","unstructured":"Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA\/PLA nanoparticles. J Pharm Sci. 2004;93(7):1804\u201314.","journal-title":"J Pharm Sci"},{"issue":"3","key":"2610_CR79","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3109\/10611869609015973","volume":"4","author":"RH M\u00fcller","year":"1996","unstructured":"M\u00fcller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target. 1996;4(3):161\u201370.","journal-title":"J Drug Target"},{"issue":"3","key":"2610_CR80","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/jps.10063","volume":"91","author":"G De Rosa","year":"2002","unstructured":"De Rosa G, Quaglia F, La Rotonda MI, Appel M, Alphandary H, Fattal E. Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide\/polyethylenimine complexes. J Pharm Sci. 2002;91(3):790\u20139.","journal-title":"J Pharm Sci"},{"key":"2610_CR81","doi-asserted-by":"crossref","unstructured":"Deivayanai VC, Thamarai P, Karishma S, Saravanan A, Yaashikaa PR, Vickram AS, et al. A comprehensive review on advances in nanoparticle-mediated cancer therapeutics: current research and future perspectives. Cancer Pathogenesis Ther. 2024;3(4):293\u2013308.","DOI":"10.1016\/j.cpt.2024.11.002"},{"issue":"5","key":"2610_CR82","doi-asserted-by":"publisher","first-page":"e09394","DOI":"10.1016\/j.heliyon.2022.e09394","volume":"8","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):e09394.","journal-title":"Heliyon"},{"key":"2610_CR83","first-page":"100281","volume":"8","author":"J Prielo\u017en\u00e1","year":"2024","unstructured":"Prielo\u017en\u00e1 J, Miku\u0161ov\u00e1 V, Miku\u0161 P. Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles. Int J Pharmaceutics: X. 2024;8:100281.","journal-title":"Int J Pharmaceutics: X"},{"issue":"10","key":"2610_CR84","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1021\/ar300159f","volume":"46","author":"C Chung","year":"2013","unstructured":"Chung C, Kim YK, Shin D, Ryoo SR, Hong BH, Min DH. Biomedical applications of graphene and graphene oxide. Acc Chem Res. 2013;46(10):2211\u201324.","journal-title":"Acc Chem Res"},{"issue":"7","key":"2610_CR85","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1039\/c2cs15355f","volume":"41","author":"RR Arvizo","year":"2012","unstructured":"Arvizo RR, Bhattacharyya S, Kudgus RA, Giri K, Bhattacharya R, Mukherjee P. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012;41(7):2943\u201370.","journal-title":"Chem Soc Rev"},{"key":"2610_CR86","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.2147\/IJN.S61670","volume":"9","author":"G Calixto","year":"2014","unstructured":"Calixto G, Bernegossi J, Fonseca-Santos B, Chorilli M. Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomed. 2014;9:3719\u201335.","journal-title":"Int J Nanomed"},{"key":"2610_CR87","doi-asserted-by":"publisher","first-page":"105599","DOI":"10.1016\/j.jddst.2024.105599","volume":"95","author":"N Rashidi","year":"2024","unstructured":"Rashidi N, Davidson M, Apostolopoulos V, Nurgali K. Nanoparticles in cancer diagnosis and treatment: progress, challenges, and opportunities. J Drug Deliv Sci Technol. 2024;95:105599.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2610_CR88","doi-asserted-by":"publisher","first-page":"1057850","DOI":"10.3389\/fimmu.2022.1057850","volume":"13","author":"T Xu","year":"2022","unstructured":"Xu T, Liu Z, Huang L, Jing J, Liu X. Modulating the tumor immune microenvironment with nanoparticles: a sword for improving the efficiency of ovarian cancer immunotherapy. Front Immunol. 2022;13:1057850.","journal-title":"Front Immunol"},{"key":"2610_CR89","doi-asserted-by":"crossref","unstructured":"Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W, et al. Revolutionizing cancer treatment: recent advances in immunotherapy. Biomedicines. 2024;12(9):2158.","DOI":"10.3390\/biomedicines12092158"},{"issue":"7","key":"2610_CR90","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.bioactmat.2020.12.010","volume":"6","author":"M Yang","year":"2021","unstructured":"Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioactive Mater. 2021;6(7):1973\u201387.","journal-title":"Bioactive Mater"},{"key":"2610_CR91","doi-asserted-by":"crossref","unstructured":"Bockamp E, Rosigkeit S, Siegl D, Schuppan D. Nano-Enhanced cancer immunotherapy: immunology encounters nanotechnology. Cells. 2020;9(9):2102.","DOI":"10.3390\/cells9092102"},{"issue":"37","key":"2610_CR92","doi-asserted-by":"publisher","first-page":"17157","DOI":"10.1039\/C9NR05371A","volume":"11","author":"Y Li","year":"2019","unstructured":"Li Y, Ayala-Orozco C, Rauta PR, Krishnan S. The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective. Nanoscale. 2019;11(37):17157\u201378.","journal-title":"Nanoscale"},{"issue":"1","key":"2610_CR93","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","volume":"6","author":"YK Chae","year":"2018","unstructured":"Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 Blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2610_CR94","doi-asserted-by":"publisher","first-page":"eaao1736","DOI":"10.1126\/sciadv.aao1736","volume":"4","author":"R Kuai","year":"2018","unstructured":"Kuai R, Yuan W, Son S, Nam J, Xu Y, Fan Y, et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci Adv. 2018;4(4):eaao1736.","journal-title":"Sci Adv"},{"issue":"9","key":"2610_CR95","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1021\/acs.nanolett.6b01994","volume":"16","author":"D Wang","year":"2016","unstructured":"Wang D, Wang T, Liu J, Yu H, Jiao S, Feng B, et al. Acid-Activatable versatile micelleplexes for PD-L1 Blockade-Enhanced cancer photodynamic immunotherapy. Nano Lett. 2016;16(9):5503\u201313.","journal-title":"Nano Lett"},{"issue":"1","key":"2610_CR96","doi-asserted-by":"publisher","first-page":"e1924","DOI":"10.1002\/wnan.1924","volume":"16","author":"D Viswanath","year":"2024","unstructured":"Viswanath D, Park J, Misra R, Pizzuti VJ, Shin SH, Doh J, et al. Nanotechnology-enhanced radiotherapy and the abscopal effect: current status and challenges of nanomaterial-based radio-immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16(1):e1924.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"19","key":"2610_CR97","doi-asserted-by":"publisher","first-page":"8948","DOI":"10.3390\/app14198948","volume":"14","author":"G-A Croitoru","year":"2024","unstructured":"Croitoru G-A, Niculescu A-G, Epistatu D, Mihaiescu DE, Antohi AM, Grumezescu AM, et al. Nanostructured drug delivery systems in immunotherapy: an updated overview of Nanotechnology-Based therapeutic innovations. Appl Sci. 2024;14(19):8948.","journal-title":"Appl Sci"},{"key":"2610_CR98","doi-asserted-by":"publisher","first-page":"1202117","DOI":"10.3389\/fonc.2023.1202117","volume":"13","author":"YH Low","year":"2023","unstructured":"Low YH, Loh CJL, Peh DYY, Chu AJM, Han S, Toh HC. Pathogenesis and therapeutic implications of EBV-associated epithelial cancers. Front Oncol. 2023;13:1202117.","journal-title":"Front Oncol"},{"issue":"14","key":"2610_CR99","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41388-025-03295-2","volume":"44","author":"S Miyauchi","year":"2025","unstructured":"Miyauchi S, Roy S, Boutros N, Sharabi AB. Virus-mediated immunosuppression in head and neck cancer. Oncogene. 2025;44(14):933\u201343.","journal-title":"Oncogene"},{"issue":"17","key":"2610_CR100","doi-asserted-by":"publisher","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","volume":"1","author":"R Mandal","year":"2016","unstructured":"Mandal R, \u015eenbabao\u011flu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17):e89829.","journal-title":"JCI Insight"},{"key":"2610_CR101","doi-asserted-by":"publisher","first-page":"1453753","DOI":"10.3389\/fimmu.2024.1453753","volume":"15","author":"HX Li","year":"2024","unstructured":"Li HX, Gong YW, Yan PJ, Xu Y, Qin G, Wen WP, et al. Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy. Front Immunol. 2024;15:1453753.","journal-title":"Front Immunol"},{"issue":"7","key":"2610_CR102","doi-asserted-by":"publisher","first-page":"e2403107","DOI":"10.1002\/adhm.202403107","volume":"14","author":"MR Thomas","year":"2025","unstructured":"Thomas MR, Badekila AK, Pai V, Bhandary SN, Rai Y. Navigating tumor microenvironment barriers with nanotherapeutic strategies for targeting metastasis. Adv Healthc Mater. 2025;14(7):e2403107.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"2610_CR103","doi-asserted-by":"publisher","first-page":"e1739","DOI":"10.1002\/wnan.1739","volume":"14","author":"CE Boone","year":"2022","unstructured":"Boone CE, Wang L, Gautam A, Newton IG, Steinmetz NF. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;14(1):e1739.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"2610_CR104","doi-asserted-by":"crossref","unstructured":"Park KS, Xu C, Sun X, Louttit C, Moon JJ. Improving STING agonist delivery for cancer immunotherapy using biodegradable mesoporous silica nanoparticles. Adv Ther (Weinh). 2020;3(10):2000130.","DOI":"10.1002\/adtp.202000130"},{"key":"2610_CR105","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PPO.0000000000000620","volume":"28","author":"DG Wallington","year":"2022","unstructured":"Wallington DG, Contessa JN, Hayman TJ. STING agonists in head and neck squamous cell carcinoma. Cancer J. 2022;28:401\u20136.","journal-title":"Cancer J"},{"issue":"11","key":"2610_CR106","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","volume":"16","author":"X Sun","year":"2021","unstructured":"Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, et al. Amplifying STING activation by Cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021;16(11):1260\u201370.","journal-title":"Nat Nanotechnol"},{"key":"2610_CR107","doi-asserted-by":"crossref","unstructured":"Park J, Jang YS, Choi JH, Ryu M, Kim GC, Byun JH, et al. Anticancer efficacy of nonthermal plasma therapy combined with PD-L1 antibody conjugated gold nanoparticles on oral squamous cell carcinoma. Appl Sci. 2021;11(10):4559.","DOI":"10.3390\/app11104559"},{"key":"2610_CR108","doi-asserted-by":"crossref","unstructured":"Zhang Y, Dong P, Yang L. The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment. Front Immunol. 2023;14:1189323.","DOI":"10.3389\/fimmu.2023.1189323"},{"issue":"3","key":"2610_CR109","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nano.2018.01.007","volume":"14","author":"SR Satapathy","year":"2018","unstructured":"Satapathy SR, Nayak A, Siddharth S, Das S, Nayak D, Kundu CN. Metallic gold and bioactive quinacrine hybrid nanoparticles inhibit oral cancer stem cell and angiogenesis by deregulating inflammatory cytokines in p53 dependent manner. Nanomedicine. 2018;14(3):883\u201396.","journal-title":"Nanomedicine"},{"key":"2610_CR110","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.onano.2023.100152","volume":"12","author":"MA Raheem","year":"2023","unstructured":"Raheem MA, Rahim MA, Gul I, Zhong X, Xiao C, Zhang H, et al. Advances in nanoparticles-based approaches in cancer theranostics. OpenNano. 2023;12:100152.","journal-title":"OpenNano"},{"issue":"15","key":"2610_CR111","doi-asserted-by":"publisher","first-page":"e35655","DOI":"10.1016\/j.heliyon.2024.e35655","volume":"10","author":"ZS Dastgheib","year":"2024","unstructured":"Dastgheib ZS, Abolmaali SS, Farahavar G, Salmanpour M, Tamaddon AM. Gold nanostructures in melanoma: advances in treatment, diagnosis, and theranostic applications. Heliyon. 2024;10(15):e35655.","journal-title":"Heliyon"},{"key":"2610_CR112","first-page":"2024","volume":"15","author":"HX Li","year":"2024","unstructured":"Li HX, Gong YW, Yan PJ, Xu Y, Qin G, Wen WP, et al. Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy. Front Immunol. 2024;15:2024.","journal-title":"Front Immunol"},{"issue":"20","key":"2610_CR113","doi-asserted-by":"publisher","first-page":"e2400012","DOI":"10.1002\/adhm.202400012","volume":"13","author":"ZH Zhou","year":"2024","unstructured":"Zhou ZH, Zhou XY, Zhang YY, Zhao TC, Li J, Zhong LP, et al. Macrophage-Capturing Self-Assembly photosensitizer nanoparticles induces immune microenvironment Re-Programming and Golgi-Responsive Immunogenic cell death in head and neck carcinoma. Adv Healthc Mater. 2024;13(20):e2400012.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"2610_CR114","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1038\/s41467-019-11719-3","volume":"10","author":"A Galstyan","year":"2019","unstructured":"Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, et al. Blood\u2013brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019;10(1):3850.","journal-title":"Nat Commun"},{"issue":"8","key":"2610_CR115","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.nano.2017.08.010","volume":"13","author":"AR Nikpoor","year":"2017","unstructured":"Nikpoor AR, Tavakkol-Afshari J, Sadri K, Jalali SA, Jaafari MR. Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: in vitro and in vivo studies. Nanomed Nanotechnol Biol Med. 2017;13(8):2671\u201382.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"2610_CR116","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12951-023-02069-w","volume":"21","author":"Y Xiang","year":"2023","unstructured":"Xiang Y, Tian M, Huang J, Li Y, Li G, Li X, et al. LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion. J Nanobiotechnol. 2023;21(1):324.","journal-title":"J Nanobiotechnol"},{"key":"2610_CR117","doi-asserted-by":"publisher","first-page":"105085","DOI":"10.1016\/j.archoralbio.2021.105085","volume":"125","author":"BBR Choi","year":"2021","unstructured":"Choi BBR, Choi JH, Kim UK, Hwang DS, Kim GC. Gold nanoparticles conjugated with programmed death-ligand 1 antibodies induce apoptosis of SCC-25 oral squamous cell carcinoma cells via programmed death-ligand 1\/signal transducer and transcription 3 pathway. Arch Oral Biol. 2021;125:105085.","journal-title":"Arch Oral Biol"},{"issue":"20","key":"2610_CR118","doi-asserted-by":"publisher","first-page":"e2500551","DOI":"10.1002\/adhm.202500551","volume":"14","author":"D Kim","year":"2025","unstructured":"Kim D, Lee JW, Rawding PA, Iida M, Kim C, Kostecki KL, et al. Dendrimer conjugates with PD-L1-Binding peptides enhance in vivo antitumor immune response. Adv Healthc Mater. 2025;14(20):e2500551.","journal-title":"Adv Healthc Mater"},{"issue":"14","key":"2610_CR119","doi-asserted-by":"publisher","first-page":"15881","DOI":"10.1021\/acsami.1c22479","volume":"14","author":"P Badiee","year":"2022","unstructured":"Badiee P, Maritz MF, Dmochowska N, Cheah E, Thierry B. Intratumoral Anti-PD-1 nanoformulation improves its biodistribution. ACS Appl Mater Interfaces. 2022;14(14):15881\u201393.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"14","key":"2610_CR120","doi-asserted-by":"publisher","first-page":"13889","DOI":"10.1021\/acsnano.4c17090","volume":"19","author":"S Yu","year":"2025","unstructured":"Yu S, Li J, Zhang J, Zeng G, Zeng B, Song S, et al. Nanosized Shikonin disrupts Tumor-Cell mismatch repair and synergizes with manganese to sensitize squamous carcinoma to immunotherapy. ACS Nano. 2025;19(14):13889\u2013905.","journal-title":"ACS Nano"},{"issue":"12","key":"2610_CR121","doi-asserted-by":"publisher","first-page":"12237","DOI":"10.1021\/acsnano.5c00322","volume":"19","author":"Y Wu","year":"2025","unstructured":"Wu Y, Diao P, Peng Y, Yang Y, Wang Y, Lv P, et al. A hybrid manganese nanoparticle simultaneously eliminates cancer stem cells and activates STING pathway to potentiate cancer immunotherapy. ACS Nano. 2025;19(12):12237\u201352.","journal-title":"ACS Nano"},{"issue":"8","key":"2610_CR122","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/1940-6207.CAPR-20-0607","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi Y, Xie TX, Leach DG, Wang B, Young S, Osman AA, et al. Local Anti-PD-1 delivery prevents progression of premalignant lesions in a 4NQO-Oral carcinogenesis mouse model. Cancer Prev Res (Phila). 2021;14(8):767\u201378.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"35","key":"2610_CR123","doi-asserted-by":"publisher","first-page":"e02154","DOI":"10.1002\/advs.202502154","volume":"12","author":"ZZ Li","year":"2025","unstructured":"Li ZZ, Liu Y, Zhou K, Cao LM, Wang GR, Wu J, et al. ORL@Cu-MOF boost Cuproptosis and suppress fatty acid metabolism for cancer lymph node metastasis synergistic therapy. Adv Sci (Weinh). 2025;12(35):e02154.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"2610_CR124","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1016\/j.oooo.2020.04.719","volume":"130","author":"DJS Santos","year":"2020","unstructured":"Santos DJS, Souza VGDE, Miranda CSS, Cardoso LPV. Immune checkpoint inhibitor expression in head and neck squamous cell carcinoma and immunotherapy use. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(3):e266\u2013e7","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"2610_CR125","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.critrevonc.2024.104536","volume":"204","author":"ZZ Li","year":"2024","unstructured":"Li ZZ, Zhou K, Wu Q, Liu B, Bu LL. Lymph node metastasis in cancer: clearing the clouds to see the dawn. Crit Rev Oncol Hematol. 2024;204:104536.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2610_CR126","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/his.13646","volume":"73","author":"S Schneider","year":"2018","unstructured":"Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, F\u00fcreder T, et al. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. Histopathology. 2018;73(4):573\u201384.","journal-title":"Histopathology"},{"issue":"1","key":"2610_CR127","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13046-023-02645-w","volume":"42","author":"R Mishra","year":"2023","unstructured":"Mishra R, Sukhbaatar A, Mori S, Kodama T. Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia. J Experimental Clin Cancer Res. 2023;42(1):132.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"7","key":"2610_CR128","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/mc.23731","volume":"63","author":"P Liu","year":"2024","unstructured":"Liu P, Ding P, Yang J, Wu H, Wu J, Guo H, et al. MicroRNA-431-5p inhibits angiogenesis, lymphangiogenesis, and lymph node metastasis by affecting TGF-\u03b21\/SMAD2\/3 signaling via ZEB1 in gastric cancer. Mol Carcinog. 2024;63(7):1378\u201391.","journal-title":"Mol Carcinog"},{"issue":"17","key":"2610_CR129","doi-asserted-by":"publisher","first-page":"e2207017","DOI":"10.1002\/advs.202207017","volume":"10","author":"J Xu","year":"2023","unstructured":"Xu J, Liu H, Wang T, Wen Z, Chen H, Yang Z, et al. CCR7 mediated mimetic dendritic cell vaccine homing in lymph node for head and neck squamous cell carcinoma therapy. Adv Sci (Weinh). 2023;10(17):e2207017.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2610_CR130","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13046-024-03190-w","volume":"43","author":"N Lu","year":"2024","unstructured":"Lu N, Jiang Q, Xu T, Gao Q, Wang Y, Huang Z, et al. LncOCMRL1 promotes oral squamous cell carcinoma growth and metastasis via the RRM2\/EMT pathway. J Exp Clin Cancer Res. 2024;43(1):267.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"2610_CR131","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.7150\/thno.80091","volume":"13","author":"S Yin","year":"2023","unstructured":"Yin S, Chen Z, Chen D, Yan D. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. Theranostics. 2023;13(5):1520\u201344.","journal-title":"Theranostics"},{"issue":"13","key":"2610_CR132","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1039\/D3NR06131K","volume":"16","author":"P Sandbhor","year":"2024","unstructured":"Sandbhor P, Palkar P, Bhat S, John G, Goda JS. Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy. Nanoscale. 2024;16(13):6330\u201364.","journal-title":"Nanoscale"},{"key":"2610_CR133","doi-asserted-by":"publisher","first-page":"7229","DOI":"10.2147\/OTT.S255491","volume":"13","author":"W Liu","year":"2020","unstructured":"Liu W, Zhang L, Xiu Z, Guo J, Wang L, Zhou Y, et al. Combination of immune checkpoint inhibitors with chemotherapy in lung cancer. Onco Targets Ther. 2020;13:7229\u201341.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"2610_CR134","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0889-8588(18)30408-8","volume":"5","author":"HA Pinto","year":"1991","unstructured":"Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am. 1991;5(4):667\u201386.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2610_CR135","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.2147\/IJN.S260760","volume":"15","author":"R Alimohammadi","year":"2020","unstructured":"Alimohammadi R, Alibeigi R, Nikpoor AR, Chalbatani GM, Webster TJ, Jaafari MR, et al. Encapsulated checkpoint blocker before chemotherapy: the optimal sequence of Anti-CTLA-4 and doxil combination therapy. Int J Nanomed. 2020;15:5279\u201388.","journal-title":"Int J Nanomed"},{"issue":"11","key":"2610_CR136","doi-asserted-by":"publisher","first-page":"19866","DOI":"10.1002\/jcp.28585","volume":"234","author":"S Golchin","year":"2019","unstructured":"Golchin S, Alimohammadi R, Rostami Nejad M, Jalali SA. Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model. J Cell Physiol. 2019;234(11):19866\u201374.","journal-title":"J Cell Physiol"},{"issue":"31","key":"2610_CR137","doi-asserted-by":"publisher","first-page":"e2100628","DOI":"10.1002\/adma.202100628","volume":"33","author":"W Ngamcherdtrakul","year":"2021","unstructured":"Ngamcherdtrakul W, Reda M, Nelson MA, Wang R, Zaidan HY, Bejan DS, et al. In situ tumor vaccination with nanoparticle Co-Delivering CpG and STAT3 SiRNA to effectively induce Whole-Body antitumor immune response. Adv Mater. 2021;33(31):e2100628.","journal-title":"Adv Mater"},{"key":"2610_CR138","doi-asserted-by":"crossref","unstructured":"Sun F, Yan P, Xiao Y, Zhang H, Shapiro SD, Xiao G, et al. Improving PD-1 Blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. Elife. 2024;12:RP89638.","DOI":"10.7554\/eLife.89638"},{"issue":"1","key":"2610_CR139","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1038\/s41467-022-31926-9","volume":"13","author":"M Reda","year":"2022","unstructured":"Reda M, Ngamcherdtrakul W, Nelson MA, Siriwon N, Wang R, Zaidan HY, et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat Commun. 2022;13(1):4261.","journal-title":"Nat Commun"},{"key":"2610_CR140","doi-asserted-by":"crossref","unstructured":"Haque M, Shakil MS, Mahmud KM. The promise of Nanoparticles-Based radiotherapy in cancer treatment. Cancers (Basel). 2023;15(6):1892","DOI":"10.3390\/cancers15061892"},{"issue":"4","key":"2610_CR141","first-page":"330","volume":"2","author":"D Kwatra","year":"2013","unstructured":"Kwatra D, Venugopal A, Anant S. Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer. Translational Cancer Res. 2013;2(4):330\u201342.","journal-title":"Translational Cancer Res"},{"key":"2610_CR142","doi-asserted-by":"crossref","unstructured":"Liu W, Chen B, Zheng H, Xing Y, Chen G, Zhou P, et al. Advances of nanomedicine in radiotherapy. Pharmaceutics. 2021;13(11):1757.","DOI":"10.3390\/pharmaceutics13111757"},{"key":"2610_CR143","doi-asserted-by":"crossref","unstructured":"Lamichhane P, Amin NP, Agarwal M, Lamichhane N. Checkpoint inhibition: will combination with radiotherapy and nanoparticle-mediated delivery improve efficacy? Medicines (Basel). 2018;5(4):114.","DOI":"10.3390\/medicines5040114"},{"issue":"1","key":"2610_CR144","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1038\/s41467-022-30543-w","volume":"13","author":"X Guan","year":"2022","unstructured":"Guan X, Sun L, Shen Y, Jin F, Bo X, Zhu C, et al. Nanoparticle-enhanced radiotherapy synergizes with PD-L1 Blockade to limit post-surgical cancer recurrence and metastasis. Nat Commun. 2022;13(1):2834.","journal-title":"Nat Commun"},{"key":"2610_CR145","doi-asserted-by":"crossref","unstructured":"Yun WS, Park JH, Lim DK, Ahn CH, Sun IC, Kim K. How did conventional nanoparticle-mediated photothermal therapy become hot in combination with cancer immunotherapy? Cancers (Basel). 2022;14(8):2044.","DOI":"10.3390\/cancers14082044"},{"issue":"1","key":"2610_CR146","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/fon.13.176","volume":"10","author":"RR Allison","year":"2014","unstructured":"Allison RR. Photodynamic therapy: oncologic horizons. Future Oncol. 2014;10(1):123\u20134.","journal-title":"Future Oncol"},{"issue":"4","key":"2610_CR147","doi-asserted-by":"publisher","first-page":"2300129","DOI":"10.1002\/anbr.202300129","volume":"4","author":"Y Pan","year":"2024","unstructured":"Pan Y, Xue X, Liang X-J. Nanotechnology-empowered combination cancer immunotherapies: mechanisms, synergies, and perspectives. Adv NanoBiomed Res. 2024;4(4):2300129.","journal-title":"Adv NanoBiomed Res"},{"key":"2610_CR148","doi-asserted-by":"publisher","first-page":"7185","DOI":"10.2147\/IJN.S459400","volume":"19","author":"H Sun","year":"2024","unstructured":"Sun H, Wang X, Guo Z, Hu Z, Yin Y, Duan S, et al. Fe(3)O(4) nanoparticles that modulate the polarisation of Tumor-Associated macrophages synergize with photothermal therapy and immunotherapy (PD-1\/PD-L1 Inhibitors) to enhance anti-tumor therapy. Int J Nanomed. 2024;19:7185\u2013200.","journal-title":"Int J Nanomed"},{"issue":"1","key":"2610_CR149","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s12274-022-4811-7","volume":"16","author":"J-J Zhou","year":"2023","unstructured":"Zhou J-J, Li X-H, He P-Y, Qi F-Y, Ullah MW, Li S-J, et al. Implantable versatile oxidized bacterial cellulose membrane for postoperative HNSCC treatment via photothermal-boosted immunotherapy. Nano Res. 2023;16(1):951\u201363.","journal-title":"Nano Res"},{"key":"2610_CR150","doi-asserted-by":"publisher","first-page":"150908","DOI":"10.1016\/j.cej.2024.150908","volume":"488","author":"T Liu","year":"2024","unstructured":"Liu T, Guo S, Zhang D, Xie D, Zhang X, Chen L, et al. Rhythmic mild photothermal therapy enhancing anti-PD-L1 response for oral squamous cell carcinoma immunotherapy. Chem Eng J. 2024;488:150908.","journal-title":"Chem Eng J"},{"issue":"48","key":"2610_CR151","doi-asserted-by":"publisher","first-page":"e2405470","DOI":"10.1002\/smll.202405470","volume":"20","author":"Y Yu","year":"2024","unstructured":"Yu Y, Ni Z, Xu Y, Zhang L, Liu Y, Zeng F, et al. Multi-Functional AIE phototheranostic agent enhancing \u03b1PD-L1 response for oral squamous cell carcinoma immunotherapy. Small. 2024;20(48):e2405470.","journal-title":"Small"},{"issue":"7","key":"2610_CR152","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1021\/acs.nanolett.0c00953","volume":"20","author":"J Bu","year":"2020","unstructured":"Bu J, Nair A, Iida M, Jeong WJ, Poellmann MJ, Mudd K, et al. An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy. Nano Lett. 2020;20(7):4901\u20139.","journal-title":"Nano Lett"},{"issue":"1","key":"2610_CR153","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40425-019-0550-z","volume":"7","author":"M Espinosa-Cotton","year":"2019","unstructured":"Espinosa-Cotton M, Rodman Iii SN, Ross KA, Jensen IJ, Sangodeyi-Miller K, McLaren AJ, et al. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. J Immunother Cancer. 2019;7(1):79.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2610_CR154","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/1535-7163.MCT-21-0234","volume":"21","author":"M Gilardi","year":"2022","unstructured":"Gilardi M, Saddawi-Konefka R, Wu VH, Lopez-Ramirez MA, Wang Z, Soto F, et al. Microneedle-mediated intratumoral delivery of anti-CTLA-4 promotes cDC1-dependent eradication of oral squamous cell carcinoma with limited IrAEs. Mol Cancer Ther. 2022;21(4):616\u201324.","journal-title":"Mol Cancer Ther"},{"issue":"27","key":"2610_CR155","doi-asserted-by":"publisher","first-page":"16495","DOI":"10.1021\/acs.jpcc.9b00913","volume":"123","author":"HT Phan","year":"2019","unstructured":"Phan HT, Haes AJ. What does nanoparticle stability mean? J Phys Chem C Nanomater Interfaces. 2019;123(27):16495\u2013507.","journal-title":"J Phys Chem C Nanomater Interfaces"},{"issue":"5","key":"2610_CR156","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/1061186X.2020.1722137","volume":"28","author":"S Sultana","year":"2020","unstructured":"Sultana S, Alzahrani N, Alzahrani R, Alshamrani W, Aloufi W, Ali A, et al. Stability issues and approaches to stabilised nanoparticles based drug delivery system. J Drug Target. 2020;28(5):468\u201386.","journal-title":"J Drug Target"},{"issue":"7793","key":"2610_CR157","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94\u2013101.","journal-title":"Nature"},{"issue":"4","key":"2610_CR158","first-page":"2163","volume":"13","author":"D Zhou","year":"2021","unstructured":"Zhou D, Wang J, Wang J, Liu X. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of HNSCC with or without HPV infection. Am J Translational Res. 2021;13(4):2163.","journal-title":"Am J Translational Res"},{"issue":"1","key":"2610_CR159","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41368-021-00131-7","volume":"13","author":"A Elmusrati","year":"2021","unstructured":"Elmusrati A, Wang J, Wang C-Y. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2021;13(1):24.","journal-title":"Int J Oral Sci"},{"key":"2610_CR160","doi-asserted-by":"publisher","first-page":"110087","DOI":"10.1016\/j.radonc.2024.110087","volume":"191","author":"A Pierik","year":"2024","unstructured":"Pierik A, Poell J, Brink A, Stigter-van Walsum M, de Roest R, Poli T, et al. Intratumor genetic heterogeneity and head and neck cancer relapse. Radiother Oncol. 2024;191:110087.","journal-title":"Radiother Oncol"},{"issue":"7","key":"2610_CR161","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","volume":"6","author":"Q Duan","year":"2020","unstructured":"Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605\u201318.","journal-title":"Trends Cancer"},{"issue":"13","key":"2610_CR162","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3390\/cells12131787","volume":"12","author":"A Benoit","year":"2023","unstructured":"Benoit A, Vogin G, Duhem C, Berchem G, Janji B. Lighting up the fire in the microenvironment of cold tumors: A major challenge to improve cancer immunotherapy. Cells. 2023;12(13):1787.","journal-title":"Cells"},{"issue":"5","key":"2610_CR163","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1002\/mco2.343","volume":"4","author":"L Wang","year":"2023","unstructured":"Wang L, Geng H, Liu Y, Liu L, Chen Y, Wu F, et al. Hot and cold tumors: immunological features and the therapeutic strategies. MedComm. 2023;4(5):e343.","journal-title":"MedComm"},{"key":"2610_CR164","doi-asserted-by":"publisher","first-page":"1237361","DOI":"10.3389\/fimmu.2023.1237361","volume":"14","author":"R Yang","year":"2023","unstructured":"Yang R, Chen L, Wang Y, Zhang L, Zheng X, Yang Y, et al. Tumor microenvironment responsive metal nanoparticles in cancer immunotherapy. Front Immunol. 2023;14:1237361.","journal-title":"Front Immunol"},{"key":"2610_CR165","doi-asserted-by":"crossref","unstructured":"Wu P, Han J, Gong Y, Liu C, Yu H, Xie N. Nanoparticle-Based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications. Pharmaceutics. 2022;14(10):1990.","DOI":"10.3390\/pharmaceutics14101990"},{"issue":"9","key":"2610_CR166","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351.","journal-title":"Nat Biotechnol"},{"issue":"26","key":"2610_CR167","doi-asserted-by":"publisher","first-page":"8312","DOI":"10.7150\/thno.37128","volume":"9","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Chen C, Cao Z, Shen S, Li L, Li D, et al. On-demand pegylation and depegylation of PLA-based nanocarriers via amphiphilic mPEG-TK-Ce6 for nanoenabled cancer chemotherapy. Theranostics. 2019;9(26):8312\u201320.","journal-title":"Theranostics"},{"issue":"9","key":"2610_CR168","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.7150\/thno.33280","volume":"9","author":"K Cherukula","year":"2019","unstructured":"Cherukula K, Uthaman S, Park IK. Navigate-dock-activate anti-tumor strategy: tumor micromilieu charge-switchable, hierarchically activated nanoplatform with ultrarapid tumor-tropic accumulation for trackable photothermal\/chemotherapy. Theranostics. 2019;9(9):2505\u201325.","journal-title":"Theranostics"},{"issue":"11","key":"2610_CR169","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.7150\/thno.31858","volume":"9","author":"N Song","year":"2019","unstructured":"Song N, Lou XY, Ma L, Gao H, Yang YW. Supramolecular nanotheranostics based on Pillarenes. Theranostics. 2019;9(11):3075\u201393.","journal-title":"Theranostics"},{"issue":"1","key":"2610_CR170","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/10717544.2021.1876182","volume":"28","author":"J Liang","year":"2021","unstructured":"Liang J, Yang B, Zhou X, Han Q, Zou J, Cheng L. Stimuli-responsive drug delivery systems for head and neck cancer therapy. Drug Delivery. 2021;28(1):272\u201384.","journal-title":"Drug Delivery"},{"issue":"19","key":"2610_CR171","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.3390\/polym14194245","volume":"14","author":"S Nastyshyn","year":"2022","unstructured":"Nastyshyn S, Stetsyshyn Y, Raczkowska J, Nastishin Y, Melnyk Y, Panchenko Y, et al. Temperature-responsive polymer brush coatings for advanced biomedical applications. Polymers. 2022;14(19):4245.","journal-title":"Polymers"},{"key":"2610_CR172","doi-asserted-by":"crossref","unstructured":"Park SM, Aalipour A, Vermesh O, Yu JH, Gambhir SS. Towards clinically translatable in vivo nanodiagnostics. Nat Rev Mater. 2017;2(5):17014.","DOI":"10.1038\/natrevmats.2017.14"},{"issue":"10","key":"2610_CR173","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.7150\/thno.38069","volume":"10","author":"P Mi","year":"2020","unstructured":"Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10(10):4557\u201388.","journal-title":"Theranostics"},{"issue":"6","key":"2610_CR174","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1021\/acsabm.1c00150","volume":"4","author":"A Sikder","year":"2021","unstructured":"Sikder A, Chaudhuri A, Mondal S, Singh NP. Recent advances on stimuli-responsive combination therapy against multidrug-resistant bacteria and biofilm. ACS Appl Bio Mater. 2021;4(6):4667\u201383.","journal-title":"ACS Appl Bio Mater"},{"issue":"20","key":"2610_CR175","doi-asserted-by":"publisher","first-page":"2208995","DOI":"10.1002\/adma.202208995","volume":"35","author":"M Liu","year":"2023","unstructured":"Liu M, Yang M, Wan X, Tang Z, Jiang L, Wang S. From nanoscopic to macroscopic materials by stimuli-responsive nanoparticle aggregation. Adv Mater. 2023;35(20):2208995.","journal-title":"Adv Mater"},{"issue":"5","key":"2610_CR176","doi-asserted-by":"publisher","first-page":"2103444","DOI":"10.1002\/advs.202103444","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lin Y, Lin Z, Wei Q, Qian J, Ruan R, et al. Stimuli-responsive nanoparticles for controlled drug delivery in synergistic cancer immunotherapy. Adv Sci. 2022;9(5):2103444.","journal-title":"Adv Sci"},{"key":"2610_CR177","doi-asserted-by":"publisher","first-page":"597634","DOI":"10.3389\/fmolb.2020.597634","volume":"7","author":"A Mohapatra","year":"2021","unstructured":"Mohapatra A, Uthaman S, Park I-K. External and internal stimuli-responsive metallic nanotherapeutics for enhanced anticancer therapy. Front Mol Biosci. 2021;7:597634.","journal-title":"Front Mol Biosci"},{"issue":"7","key":"2610_CR178","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.7150\/thno.14843","volume":"6","author":"C Qian","year":"2016","unstructured":"Qian C, Chen Y, Zhu S, Yu J, Zhang L, Feng P, et al. ATP-Responsive and Near-Infrared-Emissive nanocarriers for anticancer drug delivery and Real-Time imaging. Theranostics. 2016;6(7):1053\u201364.","journal-title":"Theranostics"},{"issue":"18","key":"2610_CR179","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1158\/1078-0432.CCR-12-1414","volume":"18","author":"T Lammers","year":"2012","unstructured":"Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized nanomedicine. Clin Cancer Res. 2012;18(18):4889\u201394.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2610_CR180","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.addr.2012.08.004","volume":"64","author":"S Liu","year":"2012","unstructured":"Liu S. Epigenetics advancing personalized nanomedicine in cancer therapy. Adv Drug Deliv Rev. 2012;64(13):1532\u201343.","journal-title":"Adv Drug Deliv Rev"},{"key":"2610_CR181","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-020-01905-8","volume":"22","author":"VM Vaz","year":"2021","unstructured":"Vaz VM, Kumar L. 3D printing as a promising tool in personalized medicine. AAPS PharmSciTech. 2021;22:1\u201320.","journal-title":"AAPS PharmSciTech"},{"issue":"02","key":"2610_CR182","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.wjorl.2016.05.003","volume":"2","author":"KP McMullen","year":"2016","unstructured":"McMullen KP, Chalmers JJ, Lang JC, Kumar P, Jatana KR. Circulating tumor cells in head and neck cancer: A review. World J otorhinolaryngology-head Neck Surg. 2016;2(02):109\u201316.","journal-title":"World J otorhinolaryngology-head Neck Surg"},{"issue":"8","key":"2610_CR183","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00262-021-03107-y","volume":"71","author":"C Zamora Atenza","year":"2022","unstructured":"Zamora Atenza C, Anguera G, Riudavets Meli\u00e0 M, De Alserawan L, Sullivan I, Barba Joaquin A, et al. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. Cancer Immunol Immunother. 2022;71(8):1823\u201335.","journal-title":"Cancer Immunol Immunother"},{"key":"2610_CR184","doi-asserted-by":"publisher","first-page":"915094","DOI":"10.3389\/fimmu.2022.915094","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Ni Y, Liang X, Lin Y, An B, He X, et al. Mechanisms of tumor resistance to immune checkpoint Blockade and combination strategies to overcome resistance. Front Immunol. 2022;13:915094.","journal-title":"Front Immunol"},{"key":"2610_CR185","doi-asserted-by":"crossref","unstructured":"Masarwy R, Breier D, Stotsky-Oterin L, Ad\u2010El N, Qassem S, Naidu GS, et al. Targeted CRISPR\/Cas9 lipid nanoparticles elicits therapeutic genome editing in head and neck cancer. Adv Sci. 2024;12(7):e2411032.","DOI":"10.1002\/advs.202411032"},{"issue":"12","key":"2610_CR186","doi-asserted-by":"publisher","first-page":"e1674605","DOI":"10.1080\/2162402X.2019.1674605","volume":"8","author":"H Stamm","year":"2019","unstructured":"Stamm H, Oliveira-Ferrer L, Grossjohann EM, Muschhammer J, Thaden V, Brauneck F, et al. Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. Oncoimmunology. 2019;8(12):e1674605.","journal-title":"Oncoimmunology"},{"issue":"2","key":"2610_CR187","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DBT Cox","year":"2015","unstructured":"Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121\u201331.","journal-title":"Nat Med"},{"issue":"10","key":"2610_CR188","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1021\/acsami.2c22584","volume":"15","author":"J Liu","year":"2023","unstructured":"Liu J, Li G, Guo H, Ni C, Gao Y, Cao X, et al. Dual-responsive core\u2013shell tecto dendrimers enable efficient gene editing of cancer cells to boost immune checkpoint Blockade therapy. ACS Appl Mater Interfaces. 2023;15(10):12809\u201321.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"7","key":"2610_CR189","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.3390\/ijms22073532","volume":"22","author":"Y-C Chen","year":"2021","unstructured":"Chen Y-C, Lai Y-S, Hsuuw Y-D, Chang K-T. Withholding of M-CSF supplement reprograms macrophages to M2-like via endogenous CSF-1 activation. Int J Mol Sci. 2021;22(7):3532.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2610_CR190","doi-asserted-by":"publisher","first-page":"2208059","DOI":"10.1002\/adma.202208059","volume":"35","author":"C Zhao","year":"2023","unstructured":"Zhao C, Cheng Y, Huang P, Wang C, Wang W, Wang M, et al. X-ray\u2010guided in situ genetic engineering of macrophages for sustained cancer immunotherapy. Adv Mater. 2023;35(14):2208059.","journal-title":"Adv Mater"},{"issue":"10","key":"2610_CR191","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/07357907.2024.2407424","volume":"42","author":"Y Ye","year":"2024","unstructured":"Ye Y, Cao Z. Glucose metabolism and glucose transporters in head and neck squamous cell carcinoma. Cancer Invest. 2024;42(10):827\u201344.","journal-title":"Cancer Invest"},{"issue":"5","key":"2610_CR192","first-page":"641","volume":"17","author":"H Ju","year":"2022","unstructured":"Ju H, Kim D, Oh Y-K. Lipid nanoparticle-mediated CRISPR\/Cas9 gene editing and metabolic engineering for anticancer immunotherapy. Asian J Pharm Sci. 2022;17(5):641\u201352.","journal-title":"Asian J Pharm Sci"},{"issue":"5","key":"2610_CR193","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.ijrobp.2024.01.189","volume":"118","author":"NR Siva","year":"2024","unstructured":"Siva NR, Dai J, Chardon-Robles J, Ligon J, Weidert F, Sayour E, et al. Anti-CD47 and anti-PDL1 immunotherapy synergize for anti-tumor activity in preclinical models of head and neck cancer. Int J Radiat Oncol Biol Phys. 2024;118(5):e85.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2610_CR194","doi-asserted-by":"publisher","first-page":"145796","DOI":"10.1016\/j.cej.2023.145796","volume":"474","author":"Y Xing","year":"2023","unstructured":"Xing Y, Yang J, Wang C, Kang Z, Pan Z, Tang J, et al. Time-programmed activation of CD47 disruption and Immunogenic cell death with Cas9 ribonucleoprotein nanocapsule for improved cancer immunotherapy. Chem Eng J. 2023;474:145796.","journal-title":"Chem Eng J"},{"key":"2610_CR195","doi-asserted-by":"crossref","unstructured":"Zhang Y, Sun X. Role of focal adhesion kinase in head and neck squamous cell carcinoma and its therapeutic prospect. Onco Target Ther. 2020;13:10207\u201320.","DOI":"10.2147\/OTT.S270342"},{"issue":"7","key":"2610_CR196","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41565-022-01122-3","volume":"17","author":"D Zhang","year":"2022","unstructured":"Zhang D, Wang G, Yu X, Wei T, Farbiak L, Johnson LT, et al. Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol. 2022;17(7):777\u201387.","journal-title":"Nat Nanotechnol"},{"issue":"40","key":"2610_CR197","doi-asserted-by":"publisher","first-page":"402002","DOI":"10.1088\/1361-6528\/ad5f33","volume":"35","author":"L-W Tong","year":"2024","unstructured":"Tong L-W, Hu Y-S, Yu S-J, Li C-L, Shao J-W. Current application and future perspective of CRISPR\/cas9 gene editing system mediated immune checkpoint for liver cancer treatment. Nanotechnology. 2024;35(40):402002.","journal-title":"Nanotechnology"},{"issue":"6","key":"2610_CR198","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2610_CR199","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","volume":"22","author":"MI van Poelgeest","year":"2016","unstructured":"van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, et al. Vaccination against oncoproteins of HPV16 for noninvasive Vulvar\/Vaginal lesions: lesion clearance is related to the strength of the T-Cell response. Clin Cancer Res. 2016;22(10):2342\u201350.","journal-title":"Clin Cancer Res"},{"key":"2610_CR200","doi-asserted-by":"crossref","unstructured":"Beyaert S, Machiels JP, Schmitz S. Vaccine-Based immunotherapy for head and neck cancers. Cancers (Basel). 2021;13(23):6041.","DOI":"10.3390\/cancers13236041"},{"key":"2610_CR201","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jconrel.2015.02.006","volume":"203","author":"S Rahimian","year":"2015","unstructured":"Rahimian S, Fransen MF, Kleinovink JW, Christensen JR, Amidi M, Hennink WE, et al. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and Poly IC as therapeutic cancer vaccine formulation. J Control Release. 2015;203:16\u201322.","journal-title":"J Control Release"},{"issue":"17","key":"2610_CR202","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-17-2807","volume":"24","author":"YS Tan","year":"2018","unstructured":"Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, et al. Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine. Clin Cancer Res. 2018;24(17):4242\u201355.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2610_CR203","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s00262-021-03134-9","volume":"71","author":"N Salomon","year":"2022","unstructured":"Salomon N, Selmi A, Grunwitz C, Kong A, Stanganello E, Neumaier J, et al. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer. Cancer Immunol Immunother. 2022;71(8):1975\u201388.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2610_CR204","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/imr.12863","volume":"296","author":"MO Mohsen","year":"2020","unstructured":"Mohsen MO, Augusto G, Bachmann MF. The 3Ds in virus-like particle based-vaccines: Design, delivery and dynamics. Immunol Rev. 2020;296(1):155\u201368.","journal-title":"Immunol Rev"},{"key":"2610_CR205","doi-asserted-by":"publisher","first-page":"111452","DOI":"10.1016\/j.colsurfb.2020.111452","volume":"197","author":"D Xu","year":"2021","unstructured":"Xu D, Song X, Zhou J, Ouyang X, Li J, Deng D. Virus-like Hollow mesoporous silica nanoparticles for cancer combination therapy. Colloids Surf B Biointerfaces. 2021;197:111452.","journal-title":"Colloids Surf B Biointerfaces"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02610-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:06:34Z","timestamp":1769605594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02610-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":205,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2610"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02610-4","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}